Drug Trial Radar · NCT06162728
Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)
Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
87
Actual
Start
Nov 29, 2023
Primary completion
Jul 8, 2026
Study completion Jul 8, 2026
Sponsor
- Lead sponsor
- Jasper Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 8, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial will be performed as a three-part dose escalating clinical trial where Parts 1 is open label and Parts 2 and 3 are randomized, double-blinded, and placebo-controlled. The trial is intended to determine the safety and tolerability and assess the preliminary efficacy of briquilimab in adult participants with chronic spontaneous urticaria (CSU), who remain symptomatic despite treatment with H1 antihistamines and omalizumab. Additionally, pharmacokinetic (PK) properties of briquilimab, and other pharmacodynamic (PD) parameters (such as effects on mast cells (MC), serum tryptase levels, and on allergic skin reactivity) will be investigated.
Conditions
- Chronic Spontaneous Urticaria
Interventions
BriquilimabDrug
Subcutaneous Administration
PlaceboOther
Placebo Comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the safety and tolerability of briquilimabTime frame: From signing the informed consent form (ICF) through end of trial (EOT) visit (up to 48 weeks)
Locations
23 sites in 2 countries. Site status is shown where the registry gives one.
Site 118
Birmingham, Alabama
Site 108
Little Rock, Arkansas
Site 105
San Diego, California
Site 113
Miami, Florida
Site 116
Tampa, Florida
Site 109
Boise, Idaho
Site 124
Springfield, Illinois
Site 110
Indianapolis, Indiana
Site 122
Overland Park, Kansas
Site 123
Lafayette, Louisiana
Site 101
Baltimore, Maryland
Site 104
Chevy Chase, Maryland
Site 121
White Marsh, Maryland
Site 103
Cincinnati, Ohio
Site 111
Murray, Utah
Site 115
Seattle, Washington
Site 201
Berlin, Germany
Site 211
Buxtehude, Germany
Site 209
Dresden, Germany
Site 206
Lübeck, Germany
Site 202
Marburg, Germany
Site 210
München, Germany
Site 204
Münster, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.